EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors

Image of EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors

THERAPEUTIC CLASS

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors

Li C - Personal Name;

Lung adenocarcinoma with EGFR activating mutations will inevitably acquire resistance to first generation TKIs. Acquired EGFR T790M mutation causes about 50% of these resistance cases. Droplet digital PCR ddPCR) and cobas enables quantification of T790M mutation. Whether these methods can predict clinical response of osimertinib treatment is unknown.

Availability

Titan Center Location name is not set

REQJ728-02

Available

Detail Information

Series Title: -
Call Number: -
Publisher: : .,
Collation: -
Language: English
ISBN/ISSN: -
Classification: NONE
Content Type: LITERATURE
Media Type: -
Carrier Type: -
Edition: -
Subject(s): Oncology
Specific Detail Info: Diagnostic Pathology (2018) 13:49 Diagnostic Pathology (2018) 13:49
Statement of Responsibility: -

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors

Availability

Detail Information

Other version/related

File Attachment

Comments